The aim of our study is to investigate whether of GLP1 receptor agonist have a pleiotropic metabolic effect and global impact to decrease cardiovascular risk and also reduce the risk of hepatic fibrosis in patients with MASLD. Here, GLP1R is linked to Hepatic fibrosis.